Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCE-AID deucrictibant prophylaxis study in acquired C1-inhibitor deficiency
NL-OMON51499Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deucrictibant in C1 inhibitor deficiency and acquired C1 esterase inhibitor deficiency (AAE), sponsored by Amsterdam University Medical Center. Primary endpoint: Normalized investigator-confirmed angioedema attack rate. Started May 2023; status: completed.
02
Drugs
deucrictibant
03
Conditions
C1 inhibitor deficiencyacquired C1 esterase inhibitor deficiency (AAE)
Beyond the preview
Go deeper on NL-OMON51499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51499.